Nasdaq:US$16.90 (-0.82) | HKEX:HK$27.20 (-0.95) | AIM:£2.52 (-0.11)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 17 Feb 2009

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate

1 items
a090217